Beyond immunotherapeutic approaches designed to target gene-specific alterations, such as KRAS, in PDAC cells, a wide range of molecularly targeted therapies have been developed for the treatment of pancreatic cancer. This evidence concerns the gene KRAS and familial pancreatic carcinoma.